Abstract
Several cellular processes could be targeted if the complex nature of Alzheimers disease (AD) was already understood. Most of AD treatments have been focused on the inhibition of acetylcholinesterase (AChE) in order to raise the levels of its substrate, i.e. the neurotransmitter acetylcholine (ACh), to augment cognitive functions of affected patients. Effectiveness in AChE inhibition and side-effect issues of clinical (tacrine, donepezil, galanthamine and rivastigmine) as well as of novel inhibitors is reviewed here. Novel design methods for the inhibition of AChE include the use of in silico tools to predict the interactions between AChE and the desired compound, both at the active site of the enzyme, responsible of hydrolysing ACh and with the peripheral anionic site (PAS), which has been described as a promoting agent of the amyloid β-peptide (Aβ) aggregation present in the senile plaques of the brain of AD individuals.
Keywords: alzheimers disease, ache, cholinesterase inhibitors
Current Pharmaceutical Design
Title: An Overview of the Current and Novel Drugs for Alzheimers Disease with Particular Reference to Anti-Cholinesterase Compounds
Volume: 10 Issue: 25
Author(s): Marcela Colombres, Juan Paulo Sagal and Nibaldo C. Inestrosa
Affiliation:
Keywords: alzheimers disease, ache, cholinesterase inhibitors
Abstract: Several cellular processes could be targeted if the complex nature of Alzheimers disease (AD) was already understood. Most of AD treatments have been focused on the inhibition of acetylcholinesterase (AChE) in order to raise the levels of its substrate, i.e. the neurotransmitter acetylcholine (ACh), to augment cognitive functions of affected patients. Effectiveness in AChE inhibition and side-effect issues of clinical (tacrine, donepezil, galanthamine and rivastigmine) as well as of novel inhibitors is reviewed here. Novel design methods for the inhibition of AChE include the use of in silico tools to predict the interactions between AChE and the desired compound, both at the active site of the enzyme, responsible of hydrolysing ACh and with the peripheral anionic site (PAS), which has been described as a promoting agent of the amyloid β-peptide (Aβ) aggregation present in the senile plaques of the brain of AD individuals.
Export Options
About this article
Cite this article as:
Colombres Marcela, Sagal Paulo Juan and Inestrosa C. Nibaldo, An Overview of the Current and Novel Drugs for Alzheimers Disease with Particular Reference to Anti-Cholinesterase Compounds, Current Pharmaceutical Design 2004; 10 (25) . https://dx.doi.org/10.2174/1381612043383359
DOI https://dx.doi.org/10.2174/1381612043383359 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Metallic Colloid Nanotechnology, Applications in Diagnosis and Therapeutics
Current Pharmaceutical Design Pharmacokinetics of Topical Ocular Drug Delivery: Potential Uses for the Treatment of Diseases of the Posterior Segment and Beyond
Current Drug Metabolism Immunotherapeutic and Immunoregulatory Drugs in Haematologic Malignancies
Current Topics in Medicinal Chemistry The Molecular Genetics of Migraine: Toward the Identification of Responsible Genes
Current Genomics Recent Patents Concerning Modulators of Protein Kinase C
Recent Patents on DNA & Gene Sequences Heat Shock Proteins And Neuroprotection
Recent Patents on DNA & Gene Sequences Editorial (Hot Topic: Drug Discovery and Development Using Infectomics and Related Approaches Introductory Overview for Anti-Infective Agents)
Anti-Infective Agents Treatment of Central Nervous System Involvement Associated with Primary Sjogrens Syndrome
Current Pharmaceutical Design Adaptors in Toll-Like Receptor Signaling and their Potential as Therapeutic Targets
Current Drug Targets Nose-to-Brain Drug Delivery by Nanoparticles in the Treatment of Neurological Disorders
Current Medicinal Chemistry Structure Based Lead Optimization Approach in Discovery of Selective DPP4 Inhibitors
Mini-Reviews in Medicinal Chemistry Immunology and Epilepsy: Clinical and Experimental Evidence
Current Immunology Reviews (Discontinued) Tumor-Associated Macrophages as Potential Targets for Anti-Cancer Activity of Marine Invertebrate-Derived Compounds
Current Pharmaceutical Design Antifungal Therapy Used in Central Nervous System Fungal Infections
Central Nervous System Agents in Medicinal Chemistry Inorganic-organic Nanomaterials for Therapeutics and Molecular Imaging Applications
Nanoscience & Nanotechnology-Asia Synthesis of Pyrophosphate-Containing Compounds that Stimulate VγVδ2 T Cells: Application to Cancer Immunotherapy
Medicinal Chemistry Prospective Evaluation of the Dosing Regimen of Vancomycin in Children of Different Weight Categories
Current Drug Safety Glycodendrimers as Anti-Adhesion Drugs Against Type 1 Fimbriated E. coli Uropathogenic Infections
Mini-Reviews in Medicinal Chemistry Arboviral Encephalitis and RNAi Treatment
Central Nervous System Agents in Medicinal Chemistry Immunity to Tuberculosis and Novel Therapeutic Strategies
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued)